Theranostic system for directed diffusion of therapeutic and imaging agents to cancer cells
AssigneesUniversitat Politècnica de València, Consejo Superior de Investigaciones Cientificas
InventorsPablo BOTELLA ASUNCIÓN, Eva María RIVERO BUCETA
Life of this patent
Estimating the term…
Abstract
The invention relates to a multifunctional system stable in a physiological medium, which includes in the same platform an anti-carcinogenic molecule, an imaging agent and a directing molecule that interacts specifically with cancer-cell membrane receptors, the system allowing pathological tissue imaging and pharmacological action to be carried out jointly with high specificity. The intratumoral administration of the system facilitates selective diffusion to cancer cells and minimises the disadvantages of chemotherapy.
Claims29
A theranostic system comprising:
- nanoparticles of a porous material wherein said porous material has a crystalline structure that corresponds to a covalent organic framework to which the following elements are bound through terminal amino groups present in the crystalline structure thereof:
- at least one therapeutic molecule, preferably selected from a small molecule of biological or synthetic origin the molecular weight of which is less than 3,000 Da, a macromolecule, an antibody, a peptide, a protein, an enzyme, a nucleic acid or an organic polymer
- an imaging agent, preferably selected from a fluorochrome, a paramagnetic element, and a radionucleus and
- an anti-FOLH1 monoclonal antibody that interacts specifically with FOLH1 receptors,
- wherein the nanoparticles have a diameter greater than 20 nm.
2-5. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
25-26. (canceled)
The theranostic system according to claim 126, wherein the linker is 11-aminoundecanoic acid.
(canceled)
30-31. (canceled)
34-38. (canceled)
Dependencies are inferred from the claim text.